Meyerhardt JA - Search Results

1

FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.

Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC. Cleary JM, et al. Among authors: meyerhardt ja. Cancer. 2019 Jul 1;125(13):2213-2221. doi: 10.1002/cncr.32029. Epub 2019 Mar 26. Cancer. 2019. PMID: 30913304 Free PMC article. Clinical Trial.

2

Chemotherapy options for gastric cancer.

Meyerhardt JA, Fuchs CS. Meyerhardt JA, et al. Semin Radiat Oncol. 2002 Apr;12(2):176-86. doi: 10.1053/srao.2002.30823. Semin Radiat Oncol. 2002. PMID: 11979419 Review.

3

Impact of diabetes mellitus on outcomes in patients with colon cancer.

Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, Fuchs CS. Meyerhardt JA, et al. J Clin Oncol. 2003 Feb 1;21(3):433-40. doi: 10.1200/JCO.2003.07.125. J Clin Oncol. 2003. PMID: 12560431 Clinical Trial.

4

Adjuvant therapy in gastric cancer: can we prevent recurrences?

Meyerhardt JA, Fuchs CS. Meyerhardt JA, et al. Oncology (Williston Park). 2003 May;17(5):714-21, 728; discussion 728-9, 732-3. Oncology (Williston Park). 2003. PMID: 12800796 Free article. Review.

5

Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.

Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB 3rd, Macdonald JS, Fuchs CS. Meyerhardt JA, et al. Cancer. 2003 Aug 1;98(3):484-95. doi: 10.1002/cncr.11544. Cancer. 2003. PMID: 12879464 Free article. Clinical Trial.

6

Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence.

Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, Fuchs CS. Meyerhardt JA, et al. Ann Intern Med. 2003 Oct 21;139(8):649-57. doi: 10.7326/0003-4819-139-8-200310210-00008. Ann Intern Med. 2003. PMID: 14568853 Clinical Trial.

7

Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study.

Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, Schrag D, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RJ, Willett CG, MacDonald JS, Benson AB 3rd, Fuchs CS. Meyerhardt JA, et al. J Clin Oncol. 2004 Jan 1;22(1):166-74. doi: 10.1200/JCO.2004.04.172. J Clin Oncol. 2004. PMID: 14701779

8

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, O'Connell MJ, Mayer RJ, Cummings B, Willett C, Macdonald JS, Benson AB 3rd, Fuchs CS. Meyerhardt JA, et al. J Clin Oncol. 2004 Feb 15;22(4):648-57. doi: 10.1200/JCO.2004.07.121. J Clin Oncol. 2004. PMID: 14966087

9

Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.

Meyerhardt JA, Kwok A, Ratain MJ, McGovren JP, Fuchs CS. Meyerhardt JA, et al. J Clin Oncol. 2004 Apr 15;22(8):1439-46. doi: 10.1200/JCO.2004.10.043. J Clin Oncol. 2004. PMID: 15084617

10

Epidermal growth factor receptor inhibitors and colorectal cancer.

Meyerhardt JA, Fuchs CS. Meyerhardt JA, et al. Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):35-8. Oncology (Williston Park). 2004. PMID: 15685832 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

460 results

Search Page

Filters